Back to top
more

Stemline Therapeutics, Inc. (STML)

(Delayed Data from NSDQ)

$15.33 USD

15.33
344,220

+0.25 (1.66%)

Updated May 3, 2019 04:00 PM ET

After-Market: $15.33 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[STML]

Reports for Purchase

Showing records 1 - 20 ( 255 total )

Industry: Medical - Biomedical and Genetics

Record: 1

05/08/2020

Company Report

Pages: 4

Dropping Coverage Due to Announced Acquisition

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

05/05/2020

Company Report

Pages: 5

Menarini Acquires Stemline; Downgrade to Neutral; Lowering PT to $12.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

05/05/2020

Daily Note

Pages: 14

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

05/04/2020

Company Report

Pages: 5

DOWNGRADING to NEUTRAL, Menarini to Acquire STML

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

04/03/2020

Daily Note

Pages: 53

Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 27

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

03/27/2020

Industry Report

Pages: 53

Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 20

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

03/26/2020

Industry Report

Pages: 9

From Underneath The Rubble Sing a Rebel Song

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

03/17/2020

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

03/17/2020

Company Report

Pages: 6

4Q and Full-Year 2019 Financial Results Reported; Reiterate Buy; Lowering PT to $18

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

03/17/2020

Company Report

Pages: 5

ELZONRIS Bouncing Around, But Upside From These Levels

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

03/03/2020

Company Report

Pages: 6

Positive Pivotal XPO1 Inhibitor Data Bolster SL-801 Prospects; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

02/14/2020

Industry Report

Pages: 53

Weekly Retail Sales Tracker for Hem. Malignancies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

02/07/2020

Daily Note

Pages: 53

Weekly Retail Sales Tracker for Hem. Malignancies

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 14

01/21/2020

Company Report

Pages: 6

4Q19 Top-Line Revenue Disappoints; Reiterate Buy; Reducing PT to $20

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 15

01/17/2020

Daily Note

Pages: 3

Dropping Coverage Update

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 16

01/16/2020

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 17

01/16/2020

Company Report

Pages: 6

Preliminary 4Q19; Decreasing PT on Decelerating ELZONRIS Launch

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 18

01/10/2020

Daily Note

Pages: 62

Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 3 2020

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 19

12/11/2019

Company Report

Pages: 10

ELZONRIS Clinical Data in Myelofibrosis and Multiple Myeloma Presented; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 20

11/11/2019

Company Report

Pages: 7

3Q19; ELZONRIS Launch Going Just Fine, Myelofibrosis Update Next at ASH

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party
// eof